Omega Healthcare Investors, Inc. Earnings Recaps
Q2 2026
Aug 1, 2026
Shares declined 1.4% following Q2 results as investors reacted cautiously to flat sequential AFFO and ongoing asset sales weighing on near-term earnings, despite management’s optimism on longer-term earnings accretion from capital redeployment.
Key takeaways
- Q2 AFFO was $0.83 per share, showing year-over-year growth but effectively flat sequentially due to a $563 million asset sale headwind.
- Asset sales occurred at an effective 6.7% cap rate on cash flow, intended to strengthen credit support for operators and fund future accretive acquisitions.
- Management signaled transaction volumes for the remainder of 2026 and into 2027 are expected to increase meaningfully.
- Recent acquisitions, including the first U.K. care home operating company, are structured to deliver higher earnings accretion compared to traditional triple net deals.
- While the underlying strategy targets long-term value, the flat near-term earnings and sales-related headwinds may have tempered investor enthusiasm.
Q1 2026
Apr 30, 2026
Omega Healthcare Investors shares drifted 0.9% lower post-earnings as results and outlook were largely in line with expectations. Though management highlighted a rising AFFO guidance midpoint and strong FAD growth, no upside surprise or disappointment was evident.
Key takeaways
- First quarter AFFO of $0.82 per share and FAD of $0.78 per share, with the FAD per share up 9.5% year-over-year.
- Management raised the low end of FY26 AFFO guidance, moving the midpoint up by $0.02 to $3.22.
- Dividend payout ratios for the quarter were 82% (AFFO) and 86% (FAD), reflecting improved coverage.
- Executed or announced $326 million in new investments year-to-date and completed or pending $480 million of asset sales, primarily the sale of 18 Communicare facilities.
- Portfolio performance remains strong, with core EBITDAR coverage at 1.58x, the highest in over a decade; Genesis restructuring and DIP loan exposure remain in focus.